Schedule Killed Pfizer IP Suit, AntiCancer Tells Fed. Circ.

Law360, New York (April 11, 2013, 6:48 PM EDT) -- California biotech firm AntiCancer Inc. on Tuesday asked the Federal Circuit to revive its suit accusing Pfizer Inc. and Crown BioScience Inc. of infringing cancer imaging patents, saying local patent rules and an unreasonable schedule stopped it from presenting its case properly.

In a reply brief, AntiCancer said it didn't get a fair opportunity to present direct evidence of Pfizer and Crown's alleged infringement. U.S. District Judge Janis L. Sammartino granted Pfizer and Crown's motion for summary judgment based on AntiCancer's patent infringement contentions, or PICs,...
To view the full article, register now.